Real-world discontinuation of hepatitis C drugs was low, but it was 3 times more likely than in clinical trials and varied by patient characteristics.
Ping Du, MD, PhD
Advertisement
Articles by Ping Du, MD, PhD
This study analyzes the current coverage designs for hepatitis C virus drugs by Medicare Part D plans.
Advertisement
Latest Updated Articles
- Discontinuation of New Hepatitis C Drugs Among Medicare Patients
February 12th 2020
Advertisement
Advertisement
Trending on AJMC
1
What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO
2
GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis
3
GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale
4
Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss
5